News

Neuroscientist Receives $25,000 Grant to Develop Way of Helping Advanced ALS Patients to Speak Again

The American Speech-Language-Hearing Foundation has awarded a $25,000 New Century Scholars Research Grant to neuroscientist Jonathan Brumberg to develop a brain-computer interface (BCI) that directly controls existing augmentative and alternative communication (AAC) devices. The platform is expected to aid people with profound speech and motor impairments due to neurodegenerative disorders such as…

New ALS Mouse Model Reported to Accurately Mimic Disease Pathology

University of Florida Health researchers have developed a mouse model of the most common genetic mutation that causes amyotrophic lateral sclerosis (ALS). The model, which captures the molecular, behavioral, and neurodegenerative features of the disease, could greatly aid in the development of more effective therapeutic agents. The paper detailing the model,…

Clinical Data of Promising ALS Drug Edaravone Presented at AAN Annual Meeting

Results from the Phase 3 trial of edaravone (MCI-186) in amyotrophic lateral sclerosis (ALS) were presented by Mitsubishi Tanabe Pharma Corporation at the 68th Annual Meeting of the American Academy of Neurology held April 15-21 in Vancouver, British Columbia. The Phase 3 MCI-186-19 clinical study has reportedly met its primary efficacy endpoint of mean change…

2 Young ALS Researchers Honored with Training and Development Awards at 2016 AAN Meeting

The ALS Association and the American Academy of Neurology (AAN) announced the 2016 winners of its Clinical Research Training Fellowship and Clinician-Scientist Development Award in amyotrophic lateral sclerosis (ALS) research. The awards are given annually to young clinicians who propose promising and innovative ALS studies, both to foster their professional development…

ALS Association Awards Lauren Sciences a 2nd Grant to Further Develop LAUR-301, a V-Smart Nanomedicine Platform

Lauren Sciences, LLC, which specializes in medicines for neurodegenerative disorders using its V-Smart drug delivery platform, announced that it has received a second grant from the ALS Association to continue developing LAUR-301, a V-Smart nanomedicine targeting brain areas affected by motor neuron death in amyotrophic lateral sclerosis (ALS). LAUR-301, developed using the V-Smart platform nanotechnology, is…

TRACK ALS Succeeds in Measuring Brain Inflammation Using a PET Scan and Biomarker

Researchers have succeeded in using an imaging technique to record changes and inflammation in the brain of a person with amyotrophic lateral sclerosis (ALS), using a potential biomarker of inflammation. The research, conducted at  The Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital, is part of the  TRACK ALS project to identify imaging markers of ALS, so…